/
Esperion is a commercial stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease, or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C.
$3.13
+$0.01 (+0.32%)
Price from 9 days ago
14.95% operating margin is respectable but not wide. ROIC at 57.83%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 21.3%, still solid.
At 56385067334678608x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Negative free cash flow of -$13M. The business is consuming cash, not generating it.
56385067334678608.0x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$418M
▲ +21.3% YoY
Net Income (TTM)
-$7M
▲ +56.2% YoY
Op. Margin
18.12%
▼ -1.4pp YoY
ROIC
73.71%
▲ +34.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$18M
▲ +45.4% YoY
Op. Cash Flow (TTM)
-$18M
▲ +44.6% YoY
Net Debt
-$56M
Net Cash Position
Cash & Equiv.
$156M
5Y CAGR: +12.1%
Continue Research